SGHT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SGHT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Sight Sciences's Net Cash per Share for the quarter that ended in Mar. 2024 was $1.63.
The historical rank and industry rank for Sight Sciences's Net Cash per Share or its related term are showing as below:
During the past 6 years, the highest Price-to-Net-Cash Ratio of Sight Sciences was 4.74. The lowest was 1.73. And the median was 3.24.
The historical data trend for Sight Sciences's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sight Sciences Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Net Cash per Share | Get a 7-Day Free Trial | -1.99 | -2.86 | 4.48 | 2.73 | 1.87 |
Sight Sciences Quarterly Data | |||||||||||||||||||
Dec18 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Net Cash per Share | Get a 7-Day Free Trial | 2.42 | 2.17 | 1.95 | 1.87 | 1.63 |
For the Medical Devices subindustry, Sight Sciences's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Sight Sciences's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Sight Sciences's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Sight Sciences's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as
Net Cash per Share (A: Dec. 2023 ) | |||||||
= | (Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | - | Minority Interest) | / | Shares Outstanding (EOP) |
= | (138.129 | - | 46.436 | - | 0) | / | 49.1314 |
= | 1.87 |
Sight Sciences's Net Cash per Share for the quarter that ended in Mar. 2024 is calculated as
Net Cash per Share (Q: Mar. 2024 ) | = | (Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | - | Minority Interest) | / | Shares Outstanding (EOP) |
= | (127.284 | - | 46.351 | - | 0) | / | 49.5652 |
= | 1.63 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sight Sciences (NAS:SGHT) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Thank you for viewing the detailed overview of Sight Sciences's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Jeremy B. Hayden | officer: Chief Legal Officer | 2 MUSICK, 2 MUSICK, IRVINE CA 92618 |
Sam Boong Park | officer: Chief Operating Officer | C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025 |
Paul Badawi | director, 10 percent owner, officer: President and CEO | C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025 |
David Badawi | director, officer: Chief Technology Officer | C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025 |
D1 Capital Partners L.p. | 10 percent owner | 9 WEST 57TH STREET, 36TH FLOOR, NEW YORK NY 10019 |
Staffan Encrantz | director | C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025 |
Matthew Link | officer: Chief Commercial Officer | 7475 LUSK BLVD, SAN DIEGO CA 92121 |
Catherine Mazzacco | director | C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203 |
Alison Bauerlein | officer: See remarks | 326 BOLLAY DRIVE, GOLETA CA 93117 |
James Rodberg | officer: See Remarks | C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVE., SUITE 100, MENLO PARK CA 94025 |
Tamara Fountain | director | C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656 |
Brenda Jane Larsen-becker | director | C/O SIGHT SCIENCES, INC., 3000 SAND HILL ROAD, BUILDING 3, STE 105, MENLO PARK CA 94025 |
Jesse Selnick | officer: Chief Financial Officer | C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025 |
Daniel S. Sundheim | 10 percent owner | C/O D1 CAPITAL PARTNERS L.P., 9 WEST 57TH STREET, 36TH FLOOR, NEW YORK NY 10019 |
Erica J. Rogers | director | C/O SILK ROAD MEDICAL, INC., 1213 INNSBRUCK DRIVE, SUNNYVALE CA 94089 |
From GuruFocus
By Stock market mentor Stock market mentor • 01-26-2023
By Marketwired • 07-20-2023
By sperokesalga sperokesalga • 06-09-2023
By Marketwired • 06-21-2023
By Marketwired • 10-12-2023
By sperokesalga sperokesalga • 05-01-2023
By Marketwired • 10-19-2023
By GlobeNewswire GlobeNewswire • 05-06-2023
By sperokesalga sperokesalga • 05-06-2023
By Marketwired • 09-11-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.